Global Liver Institute Launches Final Nonalcoholic Steatohepatitis (NASH) Externally-Led Patient-Focused Drug Development Meeting Outcome Report (Washington, DC, Wednesday, March 9,...
Partnership Applications Now Open Washington, DC – March 7, 2022 – Global Liver Institute (GLI) will convene the fifth International NASH Day (#NASHday) on June 9, 2022 with the theme Stop NASH...
GLI’s Liver Action Network Supports World Obesity Day to Acknowledge Strong Connection Between NASH and Obesity As members of Global Liver Institute’s Liver Action Network (LAN), the undersigned...
(Washington, D.C., March 2, 2022) – Global Liver Institute (GLI) proudly announces the expansion of the Liver Action Network (LAN) to include a partnership with Empire Liver...
(Washington, DC, Wednesday, February 16, 2022)—Today, Global Liver Institute (GLI) applauds the confirmation of the new Food and Drug Administration (FDA) Commissioner Dr. Robert Califf. On Tuesday,...
Transforming the Public Consciousness with Conversations for and about the Rare Liver Disease Community WASHINGTON, DC, FEBRUARY 1, 2022 – Global Liver Institute (GLI), a patient-led...
POLICY PERSPECTIVE Rapid advancements to policy and committees welcomed in the new year. One of the most highlighted actions was the advancement of the nomination of Dr. Robert Califf as the...
Fatty liver disease (FLD) and nonalcoholic steatohepatitis (NASH) are increasing in prevalence worldwide, creating a major global public health crisis. To adequately educate patients, practitioners,...
As we enter a third calendar year marked by COVID-19, the Omicron variant has caused pandemic peaks in cases and hospitalizations. However, we also have a greater understanding of the disease–and...
Washington, DC, January 14, 2022 – In 2021, the Global Liver Institute (GLI) formed the Liver Action Network (LAN) to better synchronize engagement across the liver advocacy...
Recent News
How the Hepatitis C Cure Affects Other Chronic ConditionsHepatitis C infection is a chronic infection of the liver by the hepatitis C virus (HCV) that continues to affect millions of people across the globe. Left untreated, infection with hepatitis C leads to...
New Administration, New Congress, and Their Health Priorities Just Starting to Take Shape The new U.S. Congress is at work in Washington, DC. It is unclear if the healthcare legislation that came so close to passage last December will be included in a March...
How to Stay Engaged Beyond Rare Liver Diseases Month – Pediatric and Rare Liver Diseases News #RareAware Campaign: Our Impact on Rare and Rural Healthcare In February, we took action to bridge healthcare gaps for rare liver disease patients in rural...
Latest Developments in Treatments In recent years, liver cancer has emerged as a significant global health concern, with increasing incidence rates and a pressing need for innovative treatment strategies. This newsletter highlights several articles that delve into the...
What’s New in 2025New Medicare Part D Updates for 2025 As of January 2025, major changes to Medicare Part D under the Inflation Reduction Act are now in effect, making prescription drugs more affordable for millions of patients. These updates include a $2,000 annual...
